1. (1) The general assembly finds and declares that:

   1. (a) Many health-care providers who have completed the training required by the federal drug enforcement agency and are eligible to provide medication for opioid use disorder are not actively providing medication for opioid use disorder to patients who would benefit from this medical service; and
   2. (b) Practice consultation services consisting of follow-up training and support, including stipends, can increase the number of health-care providers who prescribe medication for opioid use disorder and the number of patients receiving medication for opioid use disorder.

2. (2) The university of Colorado school of medicine shall:

   1. (a) Provide practice consultation services to health-care providers who are eligible to provide medication for opioid use disorder. Practice consultation services must include:

      1. (I) Staff training and workflow enhancement to encourage screening for opioid use disorder and educational materials for patients who screen positive for opioid use disorder;
      2. (II) Supporting the adoption of communication strategies that provide information to patients and referral sources, including but not limited to emergency departments, emergency medical service providers, hospitals, sheriffs departments, harm reduction organizations, and faith-based organizations; and
      3. (III) Providing access to marketing materials designed for patients and developed with patient and practitioner input.

   2. (b) Provide stipends to health-care providers who are eligible to provide medication for opioid use disorder and who have achieved certain benchmarks known to lead to an increased number of patients being managed by medication for opioid use disorder. At a minimum, the benchmarks must include:

      1. (I) Staff training and workflow enhancement to encourage screening and medication for opioid use disorder induction for patients who screen positive for opioid use disorder;
      2. (II) Adoption of marketing and communication strategies; and
      3. (III) Documentation of having provided medication for opioid use disorder to at least ten patients within a twelve-month period.
3. (3) Repealed.

Source: L. 2021: Entire part added, (SB 21-137), ch. 362, p. 2383, § 31, effective June 28. L. 2022: (3)(a) amended, (SB 22-212), ch. 421, p. 2975, § 50, effective August 10.

Editor's note: Subsection (3)(b) provided for the repeal of subsection (3), effective July 1, 2023. (See L. 2021, p. 2383.)